NCT00901914 - Study of rBet v1 Tablets | Biotech Hunter

Enrollment

483

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions

Birch Pollen-related RhinoconjunctivitisRhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL

Placebo

One sublingual tablet of matching placebo daily during approximately 5.5 months

BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months

BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months

BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months

Trial Locations (8)

National University Hospital - Allergy Unit 4222, Copenhagen

Charité universitaetsmedizin, Berlin

Public Institution Kaunas Medical University Hospital, Kaunas

NHC, Hôpitaux Universitaires de Strasbourg, Strasbourg

Institute of Immunology of FMBA, Moscow

Helsingin yliopistollinen keskussairaala, Helsinki

SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi, Lodz

Sabina RAK, Gothenburg